Director, Global Center for Pathogen & Human Health Research
Department Chair, Cancer Biology
Director, Infection Biology
Betsy B. deWindt Endowed Chair in Cancer Biology
Email: [email protected]
Location: Cleveland Clinic Main Campus
Dr. Jung leads the Department of Cancer Biology, the Infection Biology Program, and the newly-established Global Center for Pathogen & Human Health Research, which is focused on understanding of viral pathogens and the human immune responses toward preparing and protecting future public health threats. My research is divided into four areas: (1) virus-induced cancer (gamma-2 herpesvirus and hepatitis B virus); (2) emerging virus: mosquito-borne flavivirus (Dengue virus and Zika virus), tick-borne bunyavirus (Severe Fever with Thrombocytopenia virus and Heartland virus) and air-borne virus (severe acute respiratory syndrome coronavirus 2 and influenza virus); (3) therapeutic/vaccine development and stabilization, and (4) inflammation and immunity (host-pathogen standoff, programmed cell death, immune atlas of pregnancy and inflammation). The overarching goal of my research is to uncover new ways to understand infection and immunity and to rapidly develop and distribute vaccines and therapeutics to improve global health.
Dr. Jung joined Cleveland Clinic from the University of Southern California, where he was chair of Molecular Microbiology and Immunology and director of the Institute of Emerging Pathogens and Immune Diseases. He earned his PhD in microbiology from the University of California, Davis. He completed post-doctoral training and was later promoted to professor at Harvard Medical School. He is an elected fellow of the American Association for the Advancement of Science and the American Academy of Microbiology.
Fellowship - Harvard University
Virology
Cambridge, MA USA
1992
Fellowship - Harvard Medical School
Virology
Boston, MA USA
1992
Medical Education - University of California Davis Medical Center
Sacramento, CA USA
1989
Graduate School - Seoul National University
Food Microbiology
Seoul, Korea
1984
Undergraduate - Seoul National University
Food Science
Seoul, Korea
1982
Awards
My research is divided into four areas: (1) virus-induced cancer (gamma-2 herpesvirus and hepatitis B virus); (2) emerging virus: mosquito-borne flavivirus (Dengue virus and Zika virus), tick-borne bunyavirus (Severe Fever with Thrombocytopenia virus and Heartland virus) and air-borne virus (severe acute respiratory syndrome coronavirus 2 and influenza virus); (3) therapeutic/vaccine development and stabilization, and (4) inflammation and immunity (host-pathogen standoff, programmed cell death, immune atlas of pregnancy and inflammation). The overarching goal of my research is to uncover new ways to understand infection and immunity and to rapidly develop and distribute vaccines and therapeutics to improve global health.
View publications for Jae Jung, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Our education and training programs offer hands-on experience at one of the nationʼs top hospitals. Travel, publish in high impact journals and collaborate with investigators to solve real-world biomedical research questions.
Learn MoreThese findings challenge the current diagnostic criteria for congenital Zika syndrome, expanding the definition beyond skull or brain abnormalities.
Putting forth multiple candidates with different side effects and dosing schedules aims to provide more options for preventing public health threats.
The improved mRNA vaccine takes inspiration from the herpes virus to “trick” our cells into responding better to the shot.
Nanoparticle vaccines are designed to effectively deliver a lower dose with fewer side effects for at-risk people.
Using therapeutics to target the protein on the surface of mast cells could provide relief for patients with severe asthma.
The gift from the United Arab Emirates will advance cancer and pathogen research globally.
Cleveland Clinic research into anti-viral immunity identified a novel mechanism in necroptosis, a form of programmed cell death.
Dr. Jae Jung will study the natural course of infection and viral reassortment of the emerging pathogen, Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV).
Cleveland Clinic researchers to participate in NIH consortium focused on antiviral drug development.
Dr. Jung and his team of researchers published the novel COVID-19 study, which details the critical role viral gene ORF8 plays in infection and outcomes rates, using samples from Cleveland Clinic’s BioRepository.